Header Logo

Connection

SUHENDAN EKMEKCIOGLU to Bevacizumab

Back to Details
This is a "connection" page, showing publications SUHENDAN EKMEKCIOGLU has written about Bevacizumab.
SUHENDAN EKMEKCIOGLU
Connection Strength
0.023
Bevacizumab
  1. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.